Article

Histopathological criteria for additional treatment after endoscopic mucosal resection for esophageal cancer: analysis of 464 surgically resected cases

Clinical Laboratory Division, National Cancer Center Hospital, Tokyo, Japan.
Modern Pathology (Impact Factor: 6.36). 04/2006; 19(3):475-80. DOI: 10.1038/modpathol.3800557
Source: PubMed

ABSTRACT No previous reports on lymph-node metastasis (LNM) from superficial squamous cell carcinoma of the esophagus have proposed definite criteria for additional treatment after endoscopic mucosal resection (EMR). We investigated the association between histopathological factors and LNM in 464 consecutive patients with superficial squamous cell carcinoma of the esophagus who had undergone a radical esophagectomy with lymph-node dissection (14 'M1' lesions: intraepithelial tumors, 36 'M2' lesions: tumors invading the lamina propria, 50 'M3' lesions: tumors in contact with or invading the muscularis mucosa, 32 'SM1' lesions: tumors invading the most superficial 1/3 of the submucosa and 332 'SM2/3' lesions: tumors invading deeper than SM1 level). Histopathological factors including invasion depth, size, lymphatic invasion (LY), venous invasion, tumor differentiation, growth pattern, degree of nuclear atypia and histological grade were assessed for their association with LNM in 82 M3 or SM1 lesions to determine which patients need additional treatment after EMR. LNM was found in 0.0, 5.6, 18.0, 53.1 and 53.9% of the M1, M2, M3, SM1 and SM2/3 lesions, respectively. A univariate analysis showed that each of the following histopathological factors had a significant influence on LNM: invasion depth (M3 vs SM1), LY, venous invasion and histological grade. Invasion depth and LY were significantly associated with LNM in a multivariate analysis. Four out of 38 patients (10.3%) with M3 lesions without LY had LNM, whereas five out of 12 patients (41.7%) with M3 lesions and LY had LNM. Only patients with M1/2 lesions are good candidates for EMR. Invading the muscularis mucosa (M3) is a high-risk condition for LNM the same as submucosal invasion, but M3 lesions without LY can be followed up after EMR without any additional treatment.

Download full-text

Full-text

Available from: Tadakazu Shimoda, Sep 05, 2014
0 Followers
 · 
107 Views
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: In Barrett's esophagus, the stratified squamous epithelium lining the esophagus is replaced by specialized intestinal-type columnar epithelium. The prevalence of Barrett's esophagus has ranged from 0.9% to 4.5%. The rate of progression from Barrett's esophagus to esophageal adenocarcinoma is 0.5% per patient-year. Proton-pump inhibitors are the mainstay of symptom control in Barrett's patients. Nondysplastic Barrett's and Barrett's with low-grade dysplasia (LGD) are typically managed by periodic surveillance. Radiofrequency ablation is being evaluated as a modality for managing nondysplastic Barrett's and Barrett's with LGD. The options for the management of Barrett's patients with high-grade dysplasia (HGD) include endoscopic therapy, surgery, and intensive surveillance until biopsy reveals adenocarcinoma. Endoscopic therapy involves endoscopic mucosal resection (EMR) and ablation. More aggressive techniques such as endoscopic submucosal dissection and larger segment endoscopic mucosal resection are under study. In this review, we discuss the diagnosis and management of Barrett's esophagus. The recommendations from the major gastroenterologic societies and the current and investigational endoscopic modalities for the management of Barrett's esophagus with and without dysplasia are reviewed.
    Therapeutic Advances in Gastroenterology 07/2010; 3(4):227-38. DOI:10.1177/1756283X10365439
  • [Show abstract] [Hide abstract]
    ABSTRACT: Salvage surgery is one important therapeutic option after locoregional failure of definitive chemoradiotherapy (dCRT) in patients with advanced or recurrent esophageal carcinoma. We have performed cervical lymph node dissection as a salvage surgery after chemoradiotherapy in a patient with recurrent esophageal carcinoma. A 54-year-old Japanese man was admitted to our hospital because of multiple lymph node metastases after endoscopic submucosal dissection (ESD) for early-stage esophageal carcinoma. The patient underwent a circumferential ESD of early-stage esophageal carcinoma in another hospital. The esophageal carcinoma, measuring 75 × 60 mm in size, was a superficial spreading type located in the middle portion of the thoracic esophagus. Histology of the resected specimen revealed a moderately to poorly differentiated squamous cell carcinoma, and the depth of invasion was limited within the mucosal layer associated with a small area being attached to the muscularis mucosae. Five months after ESD, lymph node metastases in the regions of right recurrent nerve and the left tracheobronchus were found, for which dCRT was performed. These metastatic lymph nodes disappeared in the chest CT scan images. Lymph node metastasis in the region of the right recurrent nerve then reappeared 8 months after the completion of CRT. Considering the solitary lymph node metastasis and surgical invasiveness, lymph node dissection using a cervical approach was selected as a salvage surgery. Cervical approach for the lymph node dissection in the region of right recurrent nerve may be one feasible option as a minimally invasive salvage surgery for patients with recurrent esophageal carcinoma after dCRT.
    Esophagus 03/2009; 6(1):55-61. DOI:10.1007/s10388-008-0178-4 · 0.74 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: IntroductionLa résection muqueuse endoscopique (EMR) est un traitement curatif des cancers épidermoïdes (SCC) superficiels de l’œsophage. L’objectif de cette étude était d’évaluer l’évolution à long terme et la survie des patients traités par EMR. Patients et méthodesQuarante-quatre patients ont été traités par EMR entre février 1998 et octobre 2005 pour 49 SCC superficiels de l’œsophage. Chaque patient avait une échoendoscopie avant l’EMR. La technique utilisée était l’aspiration-section, la traction-section ou une combinaison des deux techniques. RésultatsTous les patients étaient T1N0 en échoendoscopie standard. Aucune complication majeure de l’EMR n’est survenue. Le suivi médian après le geste était de 44 mois. Un traitement curatif a été possible dans 68 % des cas (patients classés T1m1, T1m2), et aucun n’a présenté de récidive. Parmi les patients traités pour une lésion T2 (huit patients), six ont eu une radiochimiothérapie complémentaire et un est décédé des suites d’une évolution métastatique d’un cancer de l’œsophage. Les deux autres patients ont eu une chirurgie complémentaire à type d’oesophagectomie, et un d’entre eux est décédé suite à une récidive métastatique du cancer de l’œsophage. Huit patients avaient une lésion infiltrante en profondeur et présentant donc un risque potentiel d’envahissement ganglionnaire (deux T1m3, trois T1sm1, deux T1sm2 et un T1sm3). Parmi ces patients, six ont une radiochimiothérapie complémentaire et deux ont simplement été surveillés, aucun de ces patients n’a eu de récidive à long terme. ConclusionLe SCC superficiel de l’œsophage classé usT1N0 en échoendoscopie standard peut être traité curativement par une EMR avec un taux de résécabilité élevé (98 %) et un taux acceptable de complications. Dans le sous-groupe des 12 patients ayant une lésion plus infiltrante (m3 sm1, sm2, sm3 et T2) et traités par radiochimiothérapie complémentaire, la survie globale (SG) à cinq ans est excellente (91 %). IntroductionEndoscopic mucosal resection (EMR) is a curative treatment of early squamous cell carcinoma (SCC) of the esophagus. The objective was to evaluate the efficacy, safety, long-term outcome, and survival of EMR. Patients and methodsForty-four patients were treated by EMR between February 1998 and October 2005 for an early SCC of the esophagus. The technique of EMR was carried out by suction and section with cap or traction and section, or by the combination of both. ResultsForty-four patients had endoscopic treatment with resection of 49 early SCC. They were all of T1N0 stage as found by standard endoscopic ultrasound (EUS). No major complications occurred. The median endoscopic follow-up was 44 months. A curative resection (T1m1, T1m2) was achieved in 68% of cases without recurrence. Among patients with T2 lesion (16%), 6 had a radio-chemotherapy and only 1 patient died because of the metastatic evolution of esophageal cancer. The remaining 2 left patients had a complementary esophagectomy, among whom 1 died after recurrence. Eight patients had a histologically significant risk of nodes invasion (2 m3, 3 sm1, 2 sm2, and 1 sm3), and 6 had a complementary radio-chemotherapy without recurrence in the follow-up. ConclusionSCC of the esophagus shown usT1N0 in EUS can be treated curatively by endoscopic mucosal resection with a high rate of resecability (98%) and an acceptable complication rate. In the subgroup of 12 patients (m3 sm1, sm2, sm3 and T2) that were treated by complementary radiochemotherapy, the 5-year overall survival was 91%. Mots clésŒsophage–Carcinome épidermoïde superficiel–Traitement endoscopique KeywordsEsophagus–Early squamous cell carcinoma–Endoscopic treatment
    Acta Endoscopica 09/2011; 41(4):193-199. DOI:10.1007/s10190-011-0174-8 · 0.16 Impact Factor